Biopharmaceutical firms in the U.S. and Europe are turning to China’s biotech sector for new medicines, with licensing ...

The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which ...

Tough times in the industry are forcing changes in investment and governance that should result in a healthier sector, the ...

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

The drug, which functions similar to psilocybin, scored positive enough results in a mid-stage study that Reunion is now ...

RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...